康辰藥業(603590.SH):擬以1.34億元購買金草片的知識產權及項下全部權利
格隆匯4月6日丨 康辰藥業(603590.SH)公佈,公司擬以自有資金人民幣1.34億元,向北京和睦中創醫藥科技有限公司(“和睦中創”)購買其擁有的中藥新藥1.2類(原中藥第5類新藥)筋骨草總環烯醚萜苷片(“金草片”)的知識產權及項下全部權利(包括但不限於金草片的《藥物臨牀試驗批件》、相關技術成果及專利權、專利申請權)。目前和睦中創已完成“金草片”II期臨牀試驗,即將進入臨牀III期。
此次收購,將為公司業績提供新的增長點,為廣大婦科炎症患者提供消除慢性炎症和疼痛的精準有效治療選擇,對公司短期財務狀況、經營成果不會產生較大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.